Shilpa Medicare · NSE: SHILPAMED · BSE: 530549

Q1 FY25 results · Apr–Jun 2024

Shilpa Medicare reported revenue from operations of ₹292.51 crore (up 12.4% from Q1 FY24) and net profit of ₹14.06 crore (up 1095.1% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.

Consolidated · ₹ crore
ItemQ1 FY25Q1 FY24YoYQ4 FY24QoQ
Revenue from operations292.51260.17+12.4%291.69+0.3%
Other income9.441.93+389.0%2.49+278.6%
Total income301.95262.11+15.2%294.19+2.6%
Profit before share of associates & JVs and tax32.204.95+550.0%27.85+15.6%
Share of profit/(loss) of associates & JVs(3.52)(1.66)(0.14)
Net profit for the period14.061.1812x24.50−42.6%
EPS, basic (₹)1.460.14not comparable2.82not comparable
Net margin (%)4.80.58.4

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
ItemQ1 FY25Q1 FY24YoYQ4 FY24QoQ
Revenue from operations96.1283.74+14.8%87.45+9.9%
Other income31.4520.78+51.4%23.25+35.3%
Total income127.57104.52+22.1%110.70+15.2%
Profit before tax40.6910.76+278.1%11.43+256.1%
Net profit for the period28.357.90+258.8%9.74+191.1%
EPS, basic (₹)2.940.91not comparable1.12not comparable
Net margin (%)29.59.411.1
Consolidated
Filed with BSE
12 Aug 2024, 10:48 IST
Board meeting
08 Aug 2024
Period
01 Apr 2024 to 30 Jun 2024
Review status
Unaudited
Source
XBRL filing on BSE
Standalone
Filed with BSE
12 Aug 2024, 10:48 IST
Board meeting
08 Aug 2024
Period
01 Apr 2024 to 30 Jun 2024
Review status
Unaudited
Source
XBRL filing on BSE